BRPI0307070A2 - uso de antagonistas tgf-beta para tratar ou prevenir rejeição crônica de transplante - Google Patents

uso de antagonistas tgf-beta para tratar ou prevenir rejeição crônica de transplante

Info

Publication number
BRPI0307070A2
BRPI0307070A2 BRPI0307070-0A BRPI0307070A BRPI0307070A2 BR PI0307070 A2 BRPI0307070 A2 BR PI0307070A2 BR PI0307070 A BRPI0307070 A BR PI0307070A BR PI0307070 A2 BRPI0307070 A2 BR PI0307070A2
Authority
BR
Brazil
Prior art keywords
tgf
treat
transplant rejection
antagonist
prevent
Prior art date
Application number
BRPI0307070-0A
Other languages
English (en)
Inventor
Keshavjee Shaf
A. St. George Judith
Liu Mingyao
Original Assignee
Genzyme Corporation
University Health Network
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corporation, University Health Network filed Critical Genzyme Corporation
Publication of BRPI0307070A2 publication Critical patent/BRPI0307070A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/495—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus

Abstract

uso de antagonistas tgf-beta para tratar ou prevenir rejeição crônica de transplante a presente invenção refere-se ao uso eficaz de um antagonista tgf-p para tratar ou prevenir a perda da função de transplante que é aqui descrito. o uso de um antagonista tgf-p é demonstrado prevenir eficazmente a perda da função orgânica em um hospedeiro devido à rejeição crônica na qual a fibroproliferação mediada pelo tgf-p é uma característica. a expressão in situ de um antagonista tgf-p na forma de um receptor recombinante, isto é, o receptor tipo 111 de tgf-p (tgfbiiir) mostrou prevenção de bronquiolite obliterante em comparação a controles não-tratados em um modelo de transplante de pulmão de rato. este fornece um método eficaz de prevenir ou inibir a rejeição crônica de transplante de órgãos tais como pulmão, rim, fígado e coração em hospedeiros vertebrados incluindo hospedeiros humanos.
BRPI0307070-0A 2002-01-22 2003-01-21 uso de antagonistas tgf-beta para tratar ou prevenir rejeição crônica de transplante BRPI0307070A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US35052902P 2002-01-22 2002-01-22
US60/350,529 2002-01-22
PCT/US2003/001726 WO2003061587A2 (en) 2002-01-22 2003-01-21 USE OF TGF-β ANTAGONISTS TO TREAT OR TO PREVENT CHRONIC TRANSPLANT REJECTION

Publications (1)

Publication Number Publication Date
BRPI0307070A2 true BRPI0307070A2 (pt) 2019-03-26

Family

ID=27613397

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0307070-0A BRPI0307070A2 (pt) 2002-01-22 2003-01-21 uso de antagonistas tgf-beta para tratar ou prevenir rejeição crônica de transplante

Country Status (7)

Country Link
US (2) US20030180301A1 (pt)
EP (1) EP1478354A4 (pt)
JP (1) JP4564261B2 (pt)
AU (1) AU2003209308A1 (pt)
BR (1) BRPI0307070A2 (pt)
CA (1) CA2473829A1 (pt)
WO (1) WO2003061587A2 (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2388441A1 (en) * 2002-06-10 2003-12-10 Wei-Ping Min Immunomodulation using rna interference
AU2005244012C1 (en) 2004-05-14 2013-05-02 Alexion Pharmaceuticals, Inc. Prolongation of survival of an allograft by inhibiting complement activity
JP5481028B2 (ja) * 2004-10-13 2014-04-23 ザ オハイオ ステート ユニバーシティー リサーチ ファウンデーション ウイルス関連リンパ増殖性障害を処置または予防するための方法
RU2445975C2 (ru) * 2006-03-02 2012-03-27 Алексион Фармасьютикалз, Инк. Продление срока выживаемости аллотрансплантата путем ингибирования активности комплемента
WO2008067025A2 (en) * 2006-09-29 2008-06-05 Evanston Northwestern Healthcare Oncolytic adenoviruses and uses thereof
ES2647472T3 (es) 2006-10-03 2017-12-21 Genzyme Corporation Anticuerpos contra TGF-BETA para uso en el tratamiento de lactantes con riesgo de desarrollar displasia broncopulmonar
WO2011006029A1 (en) * 2009-07-10 2011-01-13 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Artificial cell constructs for inducing immunological tolerance
CA2826453A1 (en) 2011-02-03 2012-08-09 Alexion Pharmaceuticals, Inc. Use of an anti-cd200 antibody for prolonging the survival of allografts
US9783604B2 (en) 2013-03-11 2017-10-10 Genzyme Corporation Engineered anti-TGF-beta antibodies and antigen-binding fragments
US20160184391A1 (en) 2013-08-16 2016-06-30 Alexion Pharmaceuticals, Inc. Treatment of graft rejection by administering a complement inhibitor to an organ prior to transplant
CN116655801A (zh) 2013-08-22 2023-08-29 阿塞勒隆制药公司 TGF-β受体II型变体及其用途
WO2017024171A1 (en) 2015-08-04 2017-02-09 Acceleron Pharma Inc. Methods for treating myeloproliferative disorders
WO2018204594A1 (en) 2017-05-04 2018-11-08 Acceleron Pharma Inc. Tgf-beta receptor type ii fusion proteins and uses thereof

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5654270A (en) * 1988-06-28 1997-08-05 La Jolla Cancer Research Foundation Use of fibromodulin to prevent or reduce dermal scarring
US5705609A (en) * 1988-06-28 1998-01-06 La Jolla Cancer Research Foundation Decorin fragments inhibiting cell regulatory factors
WO1990000194A1 (en) * 1988-06-28 1990-01-11 La Jolla Cancer Research Foundation Suppression of cell proliferation by decorin
US5571714A (en) * 1988-12-22 1996-11-05 Celtrix Pharmaceuticals, Inc. Monoclonal antibodies which bind both transforming growth factors β1 and β2 and methods of use
AU671606B2 (en) * 1991-10-31 1996-09-05 Whitehead Institute For Biomedical Research TGF-beta type receptor cDNAs and uses therefor
US6008011A (en) * 1991-10-31 1999-12-28 Whitehead Institute For Biomedical Research TGF-β type II receptor cDNAs
DE69228700T2 (de) * 1991-12-04 1999-09-09 Jolla Cancer Res Found Verwendung von Decorin oder Biglycan zur Herstellung eines Medikaments für die Behandlung von Diabetes-bedingter Zustände
GB9205800D0 (en) * 1992-03-17 1992-04-29 British Tech Group Treatment of fibrotic disorders
WO1993019783A1 (en) * 1992-04-01 1993-10-14 The Whittier Institute For Diabetes And Endocrinology Methods of inhibiting or enhancing scar formation in the cns
US5821234A (en) * 1992-09-10 1998-10-13 The Board Of Trustees Of The Leland Stanford Junior University Inhibition of proliferation of vascular smooth muscle cell
US5869462A (en) * 1992-09-10 1999-02-09 The Board Of Trustees Of The Leland Stanford Junior University Inhibition of proliferation of vascular smooth muscle cell
AU669256B2 (en) * 1992-10-29 1996-05-30 Celtrix Pharmaceuticals, Inc. Uses of TGF-beta receptor fragment as a therapeutic agent
US5830847A (en) * 1992-10-30 1998-11-03 Hsc Research & Development Limited Partnership Soluble TGF-β-binding endoglin polypeptides and homodimers
WO1995000103A2 (en) * 1993-06-15 1995-01-05 Il-Yang Pharm. Co., Ltd. Anti-sense oligodeoxynucleotide to fibrogenic cytokines and use thereof
DE69523750T2 (de) * 1994-05-04 2002-08-01 Mount Sinai Hospital Corp Modulatoren der cytokine der tgf-beta überfamilie und verfahren zu ihrer bestimmung
US5772995A (en) * 1994-07-18 1998-06-30 Sidney Kimmel Cancer Center Compositions and methods for enhanced tumor cell immunity in vivo
CA2156767A1 (en) * 1994-08-25 1996-02-26 Kenichi Matsunaga Binding agent for growth factor
US5834248A (en) * 1995-02-10 1998-11-10 Millennium Pharmaceuticals Inc. Compositions and methods using rchd534, a gene uregulated by shear stress
US5824655A (en) * 1995-02-15 1998-10-20 The University Of Utah Anti-transforming growth factor-β gene therapy
US5948639A (en) * 1997-04-10 1999-09-07 Millennium Pharmaceuticals, Inc. TGF-β pathway genes
AU771635B2 (en) * 1999-01-05 2004-04-01 American National Red Cross, The Methods for treating conditions associated with the accumulation of excess extracellular matrix

Also Published As

Publication number Publication date
US20090263389A1 (en) 2009-10-22
JP4564261B2 (ja) 2010-10-20
US20030180301A1 (en) 2003-09-25
WO2003061587A3 (en) 2004-01-15
CA2473829A1 (en) 2003-07-31
EP1478354A2 (en) 2004-11-24
AU2003209308A1 (en) 2003-09-02
EP1478354A4 (en) 2008-09-24
WO2003061587A2 (en) 2003-07-31
JP2005519902A (ja) 2005-07-07

Similar Documents

Publication Publication Date Title
BRPI0307070A2 (pt) uso de antagonistas tgf-beta para tratar ou prevenir rejeição crônica de transplante
CY1115870T1 (el) Ενωσεις 1,2,4-οξαδιαζολο βενζοϊκου οξεος και χρηση αυτων για μη νοηματικη καταστολη και τη θεραπεια ασθενειας
ATE430569T1 (de) Neue arzneimittel zur behandlung von chronisch obstruktiver lungenerkrankung
NO20033862D0 (no) Fremgangsmåter for forebyggelse eller behandling av inflammatoriske eller autoimmune sykdommer ved administrering av integrin-alfa-beta3-antagonister
NO20052626D0 (no) Middel for forhindring eller behandling av neuropati
NO20033839D0 (no) Inhibitorer av transplantatavvisning
ATE427116T1 (de) Behandlung von bakteriellen infektionen
NO20010882L (no) Terapier for behandling av lungesykdommer
WO2007005672A3 (en) Treatment and prevention of respiratory diseases and conditions
DE69730725D1 (de) Synthetische phosphopeptide zur behandlung von knochenerkrankheiten
NO20072934L (no) Anvendelse av Ranolazon i kombinasjon med minst ett remodelleringsmiddel for a reversere remodellering av venstre ventikkel ved behandlingen av hjertesvikt
NO20041598L (no) Fremgangsmater for behandling eller profylakse av vaskulaer betennelse ved anvendelse av sterolabsorpsjonsinhibitor(er)
DE69113848T2 (de) Verwendung von Phosphatidylglycerol(diC 18:10) zur Behandlung obstruktiver Atemwegserkrankungen.
WO2003082196A3 (en) Combination therapy using trefoil peptides
WO2007000584A8 (en) Treatment of fungal and/or protist infections
BR9708449A (pt) Composto processos para o tratamento ou profilaxia da bronquite cronica e de uma doenca pulmonar obstrutiva cronica e para preparação de uma doenca pulmonar obstrutiva cronica e para preparação de um composto e utilização de um composto
GEP20125531B (en) Reconstituted surfactants having improved properties
WO2004043456A8 (en) Cholesterol absorption inhibitors for the treatment of demyelination
CL2007002380A1 (es) Uso de compuestos derivados de 2,5-dihidroxibenceno para el tratamiento terapeutico y/o profilactico de la queratosis actinica.
EP4285929A3 (en) Combination hbv therapy
DK1594500T3 (da) Behandling af bakterielle sygdomme i respirations-organerne ved lokal applikation af fluorkinoloner
NO20053189L (no) HVC-kombinasjonsterapi.
DE60118898D1 (de) Verwendung von rekombinantem lungensurfactant zur frühbehandlung von akuten lungenerkrankungen
EE200200238A (et) Apolipoproteiin B-100 epitoobi mimeetpeptiidid, nende konkatemeer ja modifitseeritud peptiidid ningneid sisaldavad vaktsiinikompositsioonid
DK1362590T3 (da) Anvendelse af cilobradin eller farmaceutisk acceptable salte deraf til behandling eller forebyggelse af hjertesvigt

Legal Events

Date Code Title Description
B06H Technical and formal requirements: requirement cancelled [chapter 6.8 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 6.7 NA RPI NO 1870 DE 07/11/2006 POR TER SIDO INDEVIDA.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 17A ANUIDADE.